Replies to post #117205 on NorthWest Biotherapeutics Inc (NWBO)

[kabunushi]

This very small ph1/2 trial GBM IO showed amazing results and looks like a very obvious next step to possibly getting even better results out of Dc-VaxL for GBM. Please correct me if I'm wrong but I don't think that dc-VaxL FDA approval would not be limited to precisely the same TMZ dosage at this ph 3 trial. I believe that if approved then all clinicians would be free to try the higher TMZ dosage at their own discretion, not necessarily requiring another clinical trial, unless clinicians need the rigor of seeing a 2 arm trial before being confident to start moving SOC treatment in that direction.